Skip to main content
OpenTrials

Clinical trial condition

Malformations of Cortical Development, Group I

Explore clinical trials studying Malformations of Cortical Development, Group I. Study availability and eligibility vary by location and protocol.

123 public trials 31 recruiting studies
Refine in advanced search Browse all conditions

Malformations of Cortical Development, Group I trial results

Completed

A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)

NCT02544763

Conditions
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Genetic Diseases, Inborn, +17 more
Locations
  • UAB Epilepsy Center Birmingham, Alabama, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • UCLA-Pediatric Neurology Los Angeles, California, United States
  • UCSF Benioff Children's Hospital Oakland Oakland, California, United States
View all 44 locations
View Trial Details
Completed

RAPAMYCIN FOR KIDNEY ANGIOMYOLIPOMAS

NCT00126672

Conditions
Angiomyolipoma, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +20 more
Locations
  • Loma Linda University School of Medicine Loma Linda, California, United States
  • Connecticut Children's Medical Center Hartford, Connecticut, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • New York University Medical Center New York, United States
View Trial Details
Completed

Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.

NCT03525834

Conditions
Angiomyolipoma, Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, +26 more
Locations
  • Novartis Investigative Site Wuhan, Hubei, China
  • Novartis Investigative Site Shanghai, Shanghai Municipality, China
  • Novartis Investigative Site Chengdu, Sichuan, China
  • Novartis Investigative Site Beijing, China
View Trial Details
Completed

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

NCT03650452

Conditions
Brain Diseases, Brain Ischemia, CDKL5 deficiency disorder, +35 more
Locations
  • Phoenix Children's Hospital Phoenix, Arizona, United States
  • Children's Hospital Los Angeles Los Angeles, California, United States
  • Colorado Children's Hospital Aurora, Colorado, United States
  • Nicklaus Children's Hospital Miami, Florida, United States
View all 44 locations
View Trial Details
Completed

Early Biomarkers of Autism in Infants With Tuberous Sclerosis Complex (TSC)

NCT01780441

Conditions
Autism Spectrum Disorder, Autistic Disorder, Child Development Disorders, Pervasive, +18 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of California at Los Angeles Los Angeles, California, United States
  • Boston Children's Hospital Boston, Massachusetts, United States
  • Cincinnati Children's Hospital Cincinnati, Ohio, United States
View Trial Details
Completed

Topical Rapamycin to Erase Angiofibromas in TSC

NCT01526356

Conditions
Angiofibroma, Angiofibromas, Congenital Abnormalities, +16 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • UCLA Mattel Children's Hospital Los Angeles, California, United States
  • Jack & Julia Center for TSC at Oakland Children's Hospital & Research Center Oakland, California, United States
  • Kennedy Krieger Institute Baltimore, Maryland, United States
View Trial Details

Related conditions